Last reviewed · How we verify

NCT03982966: CRF

Effect of Omega 3 Fatty Acids on the Vascular Calcification Biomarkers Fetuin A and Osteoprotegerin in Patients With CRF

Completed NA Last updated 25 June 2020
What this trial tests

NA trial testing Omega 3 fatty acids (fish oil) 1000 mg/day oral in Chronic Renal Failure in 60 participants. Completed in 1 May 2020.

Timeline
1 January 2019
Primary endpoint
30 April 2020
1 May 2020

Quick facts

Lead sponsorDamanhour University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment60
Start date1 January 2019
Primary completion30 April 2020
Estimated completion1 May 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Damanhour University

Who can join

Adults 20 to 80, any sex, with Chronic Renal Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

study the effect of omega 3fatty acids on the vascular calcification biomarkers Fetuin -A and Osteoprotegerin (OPG) in dialysis patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Vascular calcification: from the perspective of crosstalk.
    Yang S, Zeng Z, Yuan Q, Chen Q, et al · · 2023 · cited 13× · PMID 37851172 · DOI 10.1186/s43556-023-00146-y

Verify or expand the search:

Other recruiting trials for Chronic Renal Failure

Currently open trials in the same condition.

Other Damanhour University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03982966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing